List of Vendor Companies in South Korea - 35

Actnova is a South Korean startup specializing in AI SaaS solutions. The company platform automates the behavioral testing process in clinical and non-clinical fields with artificial intelligence image processing technology. Actnova is also a manufacturer of materials inspection, measurement, and analysis instruments.

Technology that leverages customer value. ALPINION's an innovative and recognized ultrasound brand ‘E-CUBE' principles (‘Extreme Clarity', ‘Efficient Workflow', ‘Ergonomic Design') reflect ALPINION's technological philosophy that provides customers with uniform image quality throughout the product lifetime. ALPINION has focused on acoustic engineering and front-end technology since we initiated our ultrasound business. There has traditionally been a strong focus on back-end processing in ultrasound; however, we shifted attention to the front-end with a focus on the signal quality sent to system processors. ALPINION focuses on continuous innovation in acoustic technology. ALPINION has developed a range of transducer array types and applied them to ALPINION's innovative E-CUBE series of ultrasound systems. Based upon proprietary superior acoustic technology, ALPINION continuously strives to expand the medical business from diagnostic ultrasound to therapeutic ultrasound.

Nanocellulose commercialization provides sustainable value. ANPOLY develops technologies that enhance the performance of eco-friendly products by applying valuable nanocellulose materials made from discarded resources to various industries

Aptamer Sciences Inc. is a privately held biotech company focused on commercializing cutting-edge technologies for analysis of proteins, based on its proprietary aptamer technology platforms. Aptamer Sciences is dedicated to develop the aptamer technologies to generate high quality aptamer and in broad applications of research, diagnosis and therapeutics. Compared to conventional aptamer generating technologies, Aptamer Sciences has developed advanced aptamer technologies and thus can generate aptamers more efficiently with superior binding affinity. Aptamer Sciences has ongoing collaboration relationships with several industry partners. The Company also has research collaboration with several universities, hospitals and research organizations. Aptamer Sciences was founded in 2011 by researchers from POSTECH BIOTECH CENTER and is based in Pohang, South Korea. Aptamer Sciences is currently funded by aptamer service revenue and grants, as well as by investments from strategic investors.

Art Blood Co., Ltd. is a company that is building/developing a cell-based in vitro blood production system to solve the problem of blood for transfusion that is in short supply worldwide and has side effects. In addition, we are developing a platform to provide reagent red blood cells used to detect transfusion-related antibodies and therapeutic red blood cells that transport and express various therapeutic agents and immunostimulants.

BERTIS Inc.'s proteomics technology provides diagnostic services that detect cancer and various diseases in the early stages. Proteomics is a field that studies the roles of various proteins, their relationships, and their characteristics, and that can research proteins directly involved in disease occurrence and progression, using technology simultaneously analyze hundreds of proteins as accurate and exquisite. About 10 years ago, when there was no interest in proteomics in Korea, BERTIS Inc. pursued proteomics scientific research after seeing the global scaled potential. As a result, We have secured unique technology based on 25 million protein big data and A. I. and have grown into a leading proteomics company in Korea. And now, we are working hard to go beyond the Republic of Korea into a global representative proteomics company. We constantly communicate and endeavor with experts representing each field, including physicians, chemists, biologists, and engineers.

BMI KOREA: A DYNAMICALLY-GROWING BIOPHARMACEUTICAL COMPANY, ALWAYS CHALLENGING FOR HEALTHY LIFE OF HUMAN-BEING. BMI is a pharmaceutical and biotechnology company based in South Korea that focuses on development and commercialization of new medicines (incl. biologics) and medical devices. BMI started to operate in 2005, and for more than a decade it has been growing with successful development of new medicines and biologics based on its own novel technologies and know-hows. BMI has specialized in sterile formulation and has developed many products such as HA, PN, PDRN and Botulinum Toxin etc. One of main BMI’s assets is “Hyaluronidase”. BMI has led the market over the last 10 years with two formulations: (A liquid sterile-brand: “Hirax® and a lyophilized sterile power vial- brand: “BM Hylunidase ®”). With these experiences and expertise, BMI has recently developed new generation of it, “Recombinant Hyaluronidase” which is well-known to be used for changing monoclonal antibody’s formulation from IV to SC. On top of that, BMI provides integrated CDMO services to help other pharmaceuticals and biotech companies develop and commercialize medicines. With the most advanced cGMP facilities and R&D center in JEJU and OSONG, BMI can deliver the highly qualified DS, DP and ensure partners’ success to IND, NDA and BLA. Full of speed and customer tailored flexibility are the main strengths. For more information, please visit our website below: www.bmikr.co.kr

Boditech Med Inc. has been developing products for in-vitro diagnostics and diagnostic reagents for the past 20 years by pursuing the value of a company called "Respect for Life"​. In particular, about 60,000 units of ichroma ™ readers are installed and operated world wide, and ichroma™ CRP (C-Reactive Protein) has secured its largest market share in China, showing a unique competitiveness. Boditech Med Inc. is leading the way in exploring new markets through the automation of on-site diagnosed immunodiagnostic devices and the development of new high-sensitive diagnostic reagents. We have built up our reputation successfully by carrying out various national R & D projects based on solid technology, experience, and human resources accumulated over the years. In addition, Boditech Med Inc. is developing a smart production system that integrates digital technology and IT technology to flexibly manage the production scale. All employees of Boditech Med Inc. is making every effort with pride that we are the top leader of BT-IT convergence industry in Korea.

Celltrion is a leading biopharmaceutical company that specializes in research, development and manufacturing of innovative therapeutics. We are committed to delivering innovative and affordable medications to promote patients’ access to advanced therapies. We have been at the forefront of biotherapeutic development uncovering new ways of targeting the drivers of disease by creating next-generation biologics and small molecule products. For additional information on our guidelines, please visit: http://tinyurl.com/bdh9bxs9

Corentec designs, manufactures, and markets a full line of Orthopedic Implants focusing on the Hip, Knee and Spine Implant markets. Corentec is committed to Innovation, Product Excellence and Total Customer Satisfaction. Our focus on these core values is fundamental to our company's mission to contribute to a healthy and active society - Get Moving with Corentec.

Exosome Plus was founded in 2018to drive an extracellular vesicle (EV) revolution, bringing the best EV isolation and characterization platform in the field of regenerative therapy to bear on research wide challenges faced by pharmaceutics industry.

Big Data Analytics in Genomics.

Biologics, Small Molecules

Company goals: to build a consortium of multi-omics tools to help understand and manage bio big data from DNA to Protein in a disease specific manner, and to create a bio big data driven healthcare informatics infrastructure that uses the latest biotechnologies and information technologies to make a seamless and secure integrating platform

IMB Dx is a precision oncology company focused on developing solutions for safe & accurate cancer diagnosis & monitoring. We created AlphaLiquid®, a minimally-invasive liquid biopsy method which requires only a single blood draw to detect cancer and monitor its progress. With AlphaLiquid®, we offer a comprehensive genomic profile of the tumor and matching therapies as well as clinical trial information. Since we began our research in 2014, our goal has remained the same: to make cancer diagnosis accessible and affordable to as many cancer patients as possible. For more information, please visit us at www.imbdx.com/eng/ or contact us at support@imbdx.com.

아임웹은 개발자와 디자이너 없이도 웹사이트와 쇼핑몰을 제작할 수 있는 노코드 이커머스 솔루션입니다. 커머스 기능을 통해 빠르게 상품을 등록하고 주문부터 배송까지 한 번에 처리할 수 있습니다. 디자인 기능을 통해서는 클릭 몇 번으로 누구나 개성 있는 나만의 브랜드 웹사이트를 만들 수 있습니다. 아임웹은 2016년, 기술의 장벽에 막혀 온라인 비즈니스를 시작하지 못하는 사람들을 위해 ‘We serve the underserved'라는 비전으로 웹빌더 서비스를 시작했습니다. 비즈니스 경험이 적은 브랜드들이 기술의 어려움을 극복하고, 손쉽게 온라인 비즈니스를 시작할 수 있도록 만들었습니다. 시장의 후발주자였던 아임웹은 웹빌더 서비스로써 성공을 이끌어 냈고, 출시 5년 만에 국내에서 손꼽히는 이커머스 솔루션으로 발전했습니다. 그 결과 지금까지 약 80만 개의 크고 작은 브랜드가 아임웹과 함께 성장했고, 4조 원의 거래액을 달성했습니다. 이제 아임웹은 단순 이커머스 솔루션을 넘어 더 높은 곳을 바라봅니다. 주문 및 물류 관리, 고객 데이터, 광고 및 마케팅 등 온라인 비즈니스에 필요한 모든 기능을 제공하는 올인원 이커머스 솔루션으로 나아가고 있습니다. 이 기능들을 기술적인 지식 없이도 사용할 수 있게 만드는 것이 아임웹의 목표입니다. 어려운 기능을 누구나 사용할 수 있도록 만드는 것은 결코 쉬운 일이 아닙니다. 아임웹을 구성하는 각 조직은 고객 데이터를 기반으로 전략을 세우고 기능 고도화를 위해 치열하게 고민하고 있습니다. 또 더 많은 브랜드들이 아임웹을 잘 활용할 수 있도록 양질의 교육과 콘텐츠를 제공하고 있습니다. 아임웹은 한국과 대만뿐 아니라 세상의 모든 브랜드가 기술을 어려워하지 않고 더 많은 도전과 성장, 그리고 성공을 이룰 수 있는 글로벌 이커머스 시장을 이끌어가려고 합니다.

KogeneBiotech is a leading company in the in-vitro diagnostics industry and has developed the 1st SARS-CoV-2 Real-time PCR Kit in South Korea, January 2020. We are a representative with a significant contribution in the early diagnosis and prevention of the spread of COVID-19 successfully. KogeneBiotech – the first mover of the Real-time PCR assay – has developed more than 1,000 PCR Kits. As a result, we have established an extensive product portfolio in emerging diseases, clinical diagnostics, food safety, animal diseases, and pathogens. We strive to ensure and improve public healthcare while maintaining continuous cooperation with the government authorities, the national research institutes, the great hospitals, and medical centers.

LabInCube develops inCube materials capable of selective drug release, sustained release, and supporting complex raw materials.

Headquartered in Seoul, South Korea, LOTTE BIOLOGICS was founded in 2022 with a mission to deliver therapies that contribute to a healthier world. At the Syracuse Bio Campus in New York, LOTTE BIOLOGICS provides high-quality GMP manufacturing services for drug substances. The facility offers a total production capacity of 40,000L, supported by eight 5,000L stainless steel bioreactors. Additionally, the campus includes extensive analytical QC testing laboratories and warehouse facilities that have received approval from over 62 regulatory agencies worldwide. LOTTE BIOLOGICS is also advancing into a new area of expertise with Antibody-Drug Conjugates (ADCs) conjugation services, expected to be fully operational by early 2025. With over $80 million invested in ADC modalities, including both drug substance and conjugation capabilities on-site, we offer a seamless, end-to-end service from drug substance manufacturing to conjugation. Looking ahead to 2030, LOTTE BIOLOGICS is constructing three advanced bio plants in Songdo, South Korea. With construction of the first plant already underway and expected to be operational by 2026, each facility will feature eight 15,000L stainless steel bioreactors for large-scale commercial production, along with multiple 2,000L single-use bioreactors to meet clinical production needs. Collectively, these plants will provide a manufacturing volume exceeding 360,000L in bioreactor capacity. Through our commitment to delivering innovative medicines to patients worldwide, LOTTE BIOLOGICS aims to become a Global Top 10 CDMO company in the biopharmaceutical industry.

Conquer Cancer through AI. Lunit is a public company that develops medical AI software for cancer screening and treatment. Lunit AI can empower you to enhance diagnostic performance. Our AI for chest x-ray and 2D & 3D mammography has been validated through 100+ publications in peer-reviewed journals such as JAMA Oncology, Lancet Digital Health and Radiology, and is now in use in 3,500+ sites globally. < Lunit AI Suite for Radiology > • Lunit INSIGHT CXR, AI Solution for Chest X-ray • Lunit INSIGHT MMG, AI Solution for Mammography • Lunit INSIGHT DBT, AI Solution for Digital Breast Tomosynthesis • Lunit CXR Triage, AI solution for Chest X-ray Triage *emergency department use, available in the US only *If you are interested in Lunit Oncology, please visit Lunit Oncology’s LinkedIn page.

MEPSGEN, a biotech founded by YongTae Kim and Robert Langer in 2019, develops microengineered physiological systems so called organ-on-a-chip and uses the manufactured systems to study pathophysiological mechanisms of key diseases and screen new drug candidates for the treatment. With these studies supported by the technologies, the company has its own multiple new drug candidates, representative ones of which target Alzheimer's and brain tumors. The company specializes in developing and producing a 3D cell culture Microphysiological System platform and in discovering new therapeutics using nanomedicine technology. The products and services include improved accuracy in evaluating new drug candidates and reducing cost and duration of the development. The company carries out fundamental biological research and drug candidate test in an environment equipped with an organ-level function of connected human tissues, rather than studying in a traditional in-vitro experimental model using 2D cell culture, thereby enabling researchers to further verify the findings in more pathophysiologically relevant environments. MEPSGEN is holding many patents, patents pending, and numerous IP licenses in the biotechnology field. For more information visit www.mepsgen.com [ Industry ] Drug Discovery Drug Delivery Biotechnology [ Technology ] MEPS-X series - 3D Microphysiological System platforms MST-X series - Microvortex System, Nanoparticle manufacturing platform MG-X series – Nanomedicine, Biomimetic nanomaterial-based targeted drug delivery platforms

NGeneBio Co., Ltd. is a leading company in molecular diagnostics (MDx) and companion diagnostics (CDx), which develops and provides next generation sequencing (NGS)-based in vitro diagnostics (IVD) panel and clinical analysis software (SW). NGeneBio was founded in October 2015, headquartered in Seoul, South Korea as a joint venture between Genecurix and Korea Telecom. The company launched NGS-based hereditary breast/ovarian cancer panel (BRCAaccuTestTM) with clinical analysis SW (NGeneAnalysisTM) in 2016. BRCA NGS panel for PARP inhibitor CDx test and solid tumor/hematologic cancer NGS panels will be launched, inclusive of clinical data analysis SW platform. The mission of the company is to provide clinically validated NGS based IVD/CDx products/services with convergence of innovative bioinformatics and SW development capacity for global market. For more information, visit www.ngenebio.com.

Prestige Biologics Co., Ltd is a biopharmaceutical CMO, CDMO, CDEMO (Contract Development Engineering Manufacturing Organization) that provides complete solutions to the development and manufacturing requirements in your drug discovery from early stage to product registration and commercialization. Based on our fully established antibody drug & vaccine manufacturing capabilities, we now offer our upgraded CDMO service, CDEMO in which we provide customized engineering solutions for your manufacturing process in a customized manufacturing suite speed-built with our proprietary technology, ALITA Smart BioFactory™.

PROTEINA has developed a first-in-class protein-protein interaction (PPI) analysis platform using proprietary 'single-molecule co-immunoprecipitation' technology. Our platform enables quantitative PPI measurements at the single-molecule level, delivering analyses with unparalleled accuracy and speed. PROTEINA has accumulated extensive know-how in developing assays measuring targeted PPIs as well as the analytic capability to model the efficacy of a drug based on its PPI metrics. Our mission is to revolutionize protein analysis; developing effective, new approaches to diagnosing diseases and discovering new drug candidates using our novel technology. For more information regarding PROTEINA, please visit us at www.proteina.co.kr.

[About ROKIT Healthcare] ROKIT Healthcare is a First Mover in regenerative healthcare, pioneering innovations that reduce medical costs for governments and patients while driving healthcare transformation. Our mission is to extend healthy lifespans and enhance quality of life through cutting-edge technologies. At the heart of our vision lies the AI Hyper-Personalized Organ Regeneration Platform, a revolutionary solution designed to meet critical medical needs and redefine the future of medicine. [What We Do] - AI-Driven Organ Regeneration: Combining advanced bioprinting and AI to deliver hyper-personalized therapies for organ and tissue regeneration. - Anti-aging Bio-suppliment Products: Leading the anti-aging market with NMN, offering scientifically proven and effective solutions for better health. (ROKIT America) - Genomics: Utilizing AI-powered single-cell RNA-seq analysis to develop innovative diagnostics and precision medicine. (ROKIT Genomics) [Why ROKIT Healthcare?] We are committed to creating a sustainable and innovative healthcare ecosystem that benefits governments, healthcare providers, and patients. By addressing the root causes of medical challenges and reducing costs, we aim to make advanced healthcare accessible to all. [ROKIT Healthcare에 대하여] - ROKIT Healthcare는 재생 의료 분야의 First Mover로서, 정부와 환자의 의료비를 절감하고 의료 혁신을 주도하는 기술과 아이디어를 선도하고 있습니다. -우리의 사명은 최첨단 기술을 통해 건강 수명을 연장하고 삶의 질을 향상시키는 것입니다. 이러한 비전의 핵심에는 AI Hyper-Personalized Organ Regeneration Platform이 자리 잡고 있으며, 이는 의료의 중요한 과제를 해결하고 미래 의료의 패러다임을 재정의하는 혁신적인 솔루션입니다. [우리가 하는 일] - AI 기반 장기 재생: 첨단 바이오프린팅과 AI를 결합하여 개개인 맞춤형 장기 및 조직 재생 치료를 제공합니다. - 항노화 바이오 보충제 제품: 과학적으로 검증된 NMN으로 항노화 시장을 선도하며 건강을 위한 효과적인 솔루션을 제공합니다. (ROKIT America) - 유전체학: AI 기반 단일 세포 RNA-seq 분석을 활용하여 혁신적인 진단 및 정밀 의학 솔루션을 개발합니다. (ROKIT Genomics) [ROKIT Healthcare가 특별한 이유] 우리는 정부, 의료 제공자, 그리고 환자 모두에게 혜택을 주는 지속 가능하고 혁신적인 의료 생태계를 만들기 위해 노력하고 있습니다. 의료 문제의 근본적인 원인을 해결하고 비용을 절감함으로써, 선진 의료 기술을 모두가 접근 가능하게 만드는 것을 목표로 하고 있습니다.

Samsung Biologics is a fully integrated CDMO offering state-of-the-art contract development and manufacturing services. With proven regulatory approvals, the largest capacity, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely able to support the development and manufacturing of biologics products at every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide.

***This page has moved and is no longer active. Please follow us @SK pharmteco for all company news and updates.*** SK biotek Ireland, an SK pharmteco company, is a contract development and manufacturing organization with almost 60 years of active pharmaceutical ingredients manufacturing experience. SK biotek Ireland is the most recent addition to the SK Group. Headquartered in Seoul, Korea, SK Group is ranked in the Top 100* on the Fortune Global 500 list; creating value by taking the initiative in the field of energy and chemicals, information, telecommunications, semiconductors; employing over 109,000 associates globally with annual revenue of US$100 billion. SK biotek Ireland, based in Swords, Co. Dublin, has over 300 associates on campus, comprising of scientists, chemists, engineers, quality professionals carrying out research, development, manufacturing and marketing roles. *2020 Fortune 500 List

"ST Pharm provides reliable and timely custom manufacturing services for API following stringent quality system and close communication with the clients." Founded in 1983, ST Pharm (formerly known as Samchully Pharmaceutical) has been offering excellent custom manufacturing services of APIs and their intermediates to meet clients' high expectation for their use in pharmaceutical development in compliant to cGMP requirements. Our reliability in service, which is well-proven through decades of business relationship with many big pharmas and biotech clients, is the essence of our strength along with our expertise in process development and scale-up optimization. Historically, ST Pharm has been focusing our expertise on nucleoside based active pharmaceuticals in various antiviral drug applications; we became the world largest supplier of Thymidine in the late 1990s and Zidovudine in the mid 2000s and protected nucleosides in the early 2000s. ST Pharm has continuously been expanding its service offering, including synthesis of therapeutic oligonucleotides. In June 2010, ST Pharm became a subsidiary of Dong-A Pharmaceutical, the top pharmaceutical company in Korea. ST Pharm is committed to expanding its business scope into generic APIs and their intermediates with full support and collaboration with parent company Dong-A Pharmaceutical.

Viework creates new values by offering innovative vision and insight for all. Vieworks aspires to make a remarkable contribution to health improvement and industry growth by introducing the best imaging solution with our passion and creative talents, as well as with our imaging technology.

At Xcell Therapeutics, we believe that scientists and researchers should have the opportunity to develop groundbreaking treatments to cure disease, ensure good health, and limit animal suffering in research. That's why we have develop and produce serum-free, chemically defined media that provides for better research results and greater consistency in manufacturing. Our media is carefully designed and manufactured with precision to help our customers in bioengineering and life sciences achieve a better future for humanity.

Yuhan Corporation is an integrated healthcare company founded in 1926. It has achieved top market value and sales revenue in Korean pharmaceutical industries, and been awarded for the most respected and trusted company in Korea for recent 11 consecutive years. It has two subsidiaries, Yuhan Chemical and Yuhan Medica, and the affiliates including Joint Ventures with Janssen(Belgium), the Clorox Company(USA), and Kimbery-Clark Corporation(USA). The core business of Yuhan can be classified into Primary & Specialty care, Dietary supplement, Household & Animal care, and contract manufacturing of active pharmaceutical ingredients.